Microplegia, Miniplegia, myrocardial protection, myocardial protection cardioplegia - Adenocaine and the Thermacor 1200 from Smisson-Cartledge Biomedical

The Technology of HT

Adenocaine® is the world's first low potassium, non-depolarizing cardioplegia. Hibernation Therapeutics developed the Adenocaine® drug compound to be used as a cardioprotective cardioplegia to induce and maintain arrest of the heart and to reanimate the heart without the use of high potassium. When administered by a licensed medical professional, the drug compound quickly stops the human heart and maintains arrest throughout the procedure. Observational clincal data and preclinical studies have shown increased myocardial protection and improved outcomes utilizing the new Adenocaine® Hiberplegia™ Solution. The preclincal studies and current clinical use of the Adenocaine® cardioplegia indicate that surgery can be performed more predictably for the surgical team and with greater safety for the patient. Like a hibernating animal, the heart resumes normal function soon after the infusion of the Adenocaine® Hiberplegia™ Solution is stopped.

Derived from Nature

Hibernation Mechanisms

Hibernation Therapeutics’s new low potassium pharmacological approach to cardiovascular and related drug development has been derived from natural hibernation mechanisms.

Leading international scientists and medical practitioners have demonstrated in pre-clinical studies and clinical use the benefits of using the new Adenocaine® technology. These studies and early clinical use are leading to many practical applications of Adenocaine® technology.

Each application involves a three-pronged approach:

1. Voltage Control	- to maintain the cell's resting membrane voltage during times of stress and injury
2. Demand Management	- to down-regulate cell metabolism so less energy is required
3. Anti-inflammation	- to reduce the body's response to trauma and cell injury from ischemia, stroke, and cardiopulmonary bypass